Observational studyBMC infectious diseases2026
Procalcitonin/albumin to urea nitrogen ratio: a novel prognostic indicator for severe fever with thrombocytopenia syndrome.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSevere fever with thrombocytopenia syndrome (SFTS), caused by the novel Bunyavirus (NBV), is a tick-borne infectious disease associated with high morbidity and mortality. Currently, no effective treatment or vaccine exists for SFTS. Early identification of prognostic factors is crucial for clinical management. This study aimed to evaluate the prognostic value of the procalcitonin/albumin to urea nitrogen ratio (PAU) in SFTS patients.
methodsThis retrospective observational study enrolled 259 consecutive patients with SFTS admitted to Tongji Hospital from April 2023 to November 2024. Patients were stratified into survival (n = 172) and death (n = 87) groups based on clinical outcomes.
resultsMultivariable logistic regression identified advanced age, altered mental status (AMS), elevated PAU and high viral load as independent predictors of adverse outcome in SFTS. PAU exhibited strong discriminative performance (AUC 0.810; 95% CI 0.757–0.857; sensitivity 75.7%, specificity 73.0%), with an optimal cut-off of 0.06 µmol/L. Integration of PAU with age, viral load and AMS further improved accuracy (AUC 0.897; 95% CI 0.858–0.936). Bootstrap internal validation yielded a calibration curve closely approximating the diagonal, confirming robust predictive efficacy of the composite model.Kaplan-Meier analysis revealed significantly worse prognosis in high-PAU patients (P < 0.001).The longitudinal trend analysis revealed an increasing trend in PAU among non-survivors, while survivors exhibited a decreasing trend.
conclusionPAU represents a novel composite biomarker that integrates inflammatory and organ dysfunction parameters, providing reliable prognostic prediction for SFTS patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.